In addition, mTOR inhibitors have shown promise in treating multiple manifestations of TSC, including skin manifestations, cardiac rhabdomyoma, pulmonary lymphangioleiomyomatosis, and epilepsy, which supports the use of mTOR inhibitors as targeted multisystemic therapy for the disease [18,19]. Here, MTOR is linked to epilepsy.